MedTrace Logo

COVID19-hematological Malignancies: the Italian Hematology Alliance

NCT04352556 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 250

Last updated 2022-09-23

No results posted yet for this study

Summary

This is a retrospective/prospective, cohort, non-interventional observational study. This means that all patients with documented COVID and HM diagnosed between February 2020 and study initiation will compose the retrospective part, while those diagnosed after study approval will enter prospective part.

The total duration of the study will be 12 months.

The study population will must be older than 18 years of age with HM and SARS-CoV-2 infection. All patients with documented SARS-CoV-2 infection (COVID) and history or active hematological malignancies, who refer to any Hematological Unit will be included.

Conditions

Sponsors & Collaborators

  • Ospedale di Circolo - Fondazione Macchi

    lead OTHER

Principal Investigators

  • Francesco Passamonti, MD · Ospedale di Circolo e Fondazione Macchi, ASST Sette Laghi, Varese, Italy

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-07
Primary Completion
2022-10-01
Completion
2022-10-01

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04352556 on ClinicalTrials.gov